IMRX
Immuneering Corporation - Class A Common Stock (IMRX)
$
90About Immuneering Corporation - Class A Common Stock (IMRX)
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
Details
Daily high
$2.02
Daily low
$1.86
Price at open
$1.96
52 Week High
$3.83
52 Week Low
$1.00
Market cap
70.5M
Dividend yield
0.00%
Volume
175,553
Avg. volume
307,966
P/E ratio
-1.00
Immuneering Corporation - Class A Common Stock News
Details
Daily high
$2.02
Daily low
$1.86
Price at open
$1.96
52 Week High
$3.83
52 Week Low
$1.00
Market cap
70.5M
Dividend yield
0.00%
Volume
175,553
Avg. volume
307,966
P/E ratio
-1.00